Latest Regulatory Filings News

CLINUVEL Pharmaceuticals is preparing to elevate its American Depository Receipt program to a Nasdaq Level II listing by the end of 2025, aiming to enhance visibility and trading access in the U.S. without altering its primary ASX listing.

LTR Pharma has announced that its erectile dysfunction treatment SPONTAN now boasts an 18-month shelf life, surpassing commercial standards and paving the way for international market growth.

Winchester Energy appoints corporate lawyer Chris Zielinski as Non-Executive Director while CEO Rory McGoldrick transitions to a part-time role, signaling a strategic refocus on operational efficiency.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

LTR Pharma’s intranasal ED treatment SPONTAN achieves peak effect up to five times faster than oral tablets, according to new peer-reviewed clinical data published in a leading European journal.

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.

Platinum Asia Investments Limited (PAI) shares have been suspended following Federal Court approval of a scheme exchanging all shares for units in the Platinum Asia Fund Complex ETF (PAXX). This marks a significant structural shift for PAI investors.

Lumos Diagnostics has submitted its CLIA waiver application for FebriDx® to the FDA, backed by strong clinical data and triggering significant milestone payments. Approval could expand the U.S. market opportunity fifteen-fold to over $1 billion.

EPX Limited has raised $2 million through a discounted share placement to existing institutional investors, aiming to fuel sales expansion, explore M&A opportunities, and enhance its technology platform.

HITIQ Limited has issued over 9.4 million shares and nearly 4.7 million options under its shortfall offer, raising $206,960 and progressing its ongoing rights issue. The company also clarified a duplicate filing and updated its issued capital structure.

Hot Chili Limited has addressed an ASX query regarding a delayed filing of a director’s interest notice, attributing the lapse to an administrative oversight while reaffirming its commitment to disclosure rules.